Recent blog posts
CLDN17 Biologics Sequence Review Report 2026: Claudin-17 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN17 Biologics Sequence Review Report 2026: Claudin-17 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN17 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN20 Biologics Sequence Review Report 2026: Claudin-20 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN20 Biologics Sequence Review Report 2026: Claudin-20 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN20 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN16 Biologics Sequence Review Report 2026: Claudin-16 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN16 Biologics Sequence Review Report 2026: Claudin-16 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN16 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN14 Biologics Sequence Review Report 2026: Claudin-14 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN14 Biologics Sequence Review Report 2026: Claudin-14 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN14 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN15 Biologics Sequence Review Report 2026: Claudin-15 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN15 Biologics Sequence Review Report 2026: Claudin-15 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN15 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN11 Biologics Sequence Review Report 2026: Claudin-11 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN11 Biologics Sequence Review Report 2026: Claudin-11 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN10 Biologics Sequence Review Report 2026: Claudin-10 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN10 Biologics Sequence Review Report 2026: Claudin-10 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN12 Biologics Sequence Review Report 2026: Claudin-12 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN12 Biologics Sequence Review Report 2026: Claudin-12 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN9 Biologics Sequence Review Report 2026: Claudin-9 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN9 Biologics Sequence Review Report 2026: Claudin-9 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN9 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN7 Biologics Sequence Review Report 2026: Claudin-7 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN7 Biologics Sequence Review Report 2026: Claudin-7 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN7 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN8 Biologics Sequence Review Report 2026: Claudin-8 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN8 Biologics Sequence Review Report 2026: Claudin-8 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CLDN1 Biologics Sequence Review Report 2026: Claudin-1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CLDN1 Biologics Sequence Review Report 2026: Claudin-1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →